Bioanalysis
Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services
Greater Montréal, Québec, 11/13, 2024 — Altasciences, a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services. This core business supports both preclinical and clinical studies conducted at Altasciences’ facilities, while also offering an extensive standalone solution to meet the diverse needs of clients. By delivering high-quality, flexible bioanalytical services, Altasciences remains dedicated to advancing drug development and empowering clients across every phase of research.
For three decades now, Altasciences has taken pride in evolving their solutions to meet the needs of pharmaceutical and biotechnology companies of all sizes, including the expansion of their labs in Seattle, WA, Columbia, MO, and Laval, Quebec. Their three state-of-the-art bioanalytical laboratories feature mirrored operations and uniform protocols to maintain consistency and quality across client projects, ensuring reliable, high-quality data regardless of location. This high level of harmonization enables the seamless transfer and sharing of methods across its multiple laboratory sites, allowing the analysis of hundreds of thousands of samples efficiently.
“Our extensive bioanalytical offerings are designed to support both standalone projects and Altasciences' integrated drug development solutions. Whether for preclinical or clinical studies, we provide tailored solutions to meet specific research needs. At Altasciences, we’re committed to facilitating every phase of the scientific journey with precision and care,” said Dr. Lynne Le Sauteur, Vice President of Laboratory Sciences at Altasciences.
Altasciences’ bioanalytical services are built around a comprehensive suite of capabilities tailored for both small and large molecules. Core offerings include drug quantification, metabolite and biomarker analysis, and immunogenicity testing, to support and advance a molecule from discovery to market.
Altasciences’ bioanalytical approach focuses on three core pillars: understanding and anticipating client needs as scientists, creating innovative solutions, and fostering collaboration through transparent communication. This client-centered approach has helped Altasciences build lasting partnerships, assisting clients in meeting complex regulatory standards while maintaining scientific rigor.
To promote Altasciences’ bioanalytical services from discovery to Phase IV, they recently launched their Unveiling the Invisible video campaign to showcase how their bioanalytical solutions provide critical insights that unveil the invisible and drive the creation of innovative therapies.
View the fascinating video series here.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit Altasciences.com.
Julie-Ann Cabana
Altasciences
jcabana@altasciences.com
ISSUE NO. 42 — Managing The Complexities of Glucagon-Like Peptide-1 Receptor Agonist Drug Development
Current and future development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), or simply GLP-1s, involves complexities not only in formulation but in all areas of early-phase drug development. Developing and refining preclinical models for early efficacy signals, developing and validating the bioanalytical assays necessary for quantitation, and designing the clinical studies that deliver the most robust data in this innovative therapeutic area are all key elements of a drug development program.
In Issue 42 of The Altascientist, we review the requirements for successful GLP-1 drug development, including:
- preclinical approaches
- early-phase clinical study design
- bioanalytical techniques
- manufacturing
Two case studies are also included.
Top Life Science Resources for Fall 2024
There’s a lot of life science content out there, so for your convenience, we’ve curated a selection of expert insights, tips, case studies, and scientific and regulatory information. Catch up on what you might have missed below!
Development and Validation of LC-MS/MS Assay Methods to Determine Ubrogepant and Atogepant in Human Breast Milk
Implementation of a Semi-Automated Bead Extraction Procedure During Analyte Purification for High Throughput Immunogenicity Assays
Strategy to Increase Throughput and Method Sensitivity for Clinical Immunogenicity Studies
Development of a Hybridization LC-MS Methodology for Quantitation of siRNA in Cynomolgus Monkey
Quantitative Bioanalysis of HT-KIT Vivo-Morpholino Using Hybridization LC-MS/MS
Strategies to Improve Assay Sensitivity for Bioanalysis of Therapeutic Oligonucleotides Through Ligand Binding Assays
ISSUE NO. 41 — Immunomodulation Assessments for Clinical Trials: Sophisticated Bioanalytical Approaches to Support Complex Modalities
Immunomodulatory drugs are at the forefront for the treatment of various types of cancer, infectious diseases, and numerous autoimmune diseases, including rheumatoid arthritis, type I diabetes, lupus, and multiple sclerosis. As the complexity of these therapeutics increases, so must the sophistication of the bioanalytical assays designed to either quantify them or measure their impact on the patient.
In Issue 41 of The Altascientist, we explore common classes of immunomodulators, bioanalytical methods used to quantify them, and their associated biomarkers. Featuring two scenarios that explore the complexities of bioanalysis for immunomodulators, The Altascientist offers practical considerations for ensuring accurate bioanalysis, as well as pharmacokinetic, pharmacodynamic, and safety data in clinical trials.
This issue also covers:
• classes of immunomodulators, including monoclonal antibodies, CAR-T cells, and vaccines;
• immunotherapy trials, focusing on complex study designs and diverse patient populations; and
• bioanalytical methods and assays, including pharmacokinetics and anti-drug antibodies (ADA).